NMN/NR in Special Populations: What Transplant Recipients, People With HIV, and Other High-Risk Groups Need to Know

How NMN and NR Raise NAD+ Levels

NMN and NR are both precursors to nicotinamide adenine dinucleotide (NAD+), a coenzyme required by over 500 enzymatic reactions including those catalyzed by sirtuins, PARPs, and CD38. Age, chronic infection, and organ damage deplete the intracellular NAD+ pool. Replenishing it is the rationale behind supplementation.

The Salvage Pathway

NR enters cells through equilibrative nucleoside transporters and is phosphorylated by nicotinamide riboside kinases (NRK1 and NRK2) to form NMN. NMN is then adenylylated by NMNAT enzymes to yield NAD+ [1]. NMN itself can be dephosphorylated extracellularly to NR before cellular uptake, or it may enter some tissues directly via the transporter Slc12a8, identified in murine gut epithelium [2].

Why NAD+ Matters in Disease States

Chronic inflammation accelerates NAD+ consumption. CD38, an ectoenzyme upregulated by inflammatory cytokines, degrades NAD+ at rates that can outpace biosynthesis [3]. Conditions characterized by persistent immune activation (HIV, post-transplant inflammation, autoimmune disease) share a common downstream problem: NAD+ depletion that impairs mitochondrial function, DNA repair, and metabolic signaling.

Yoshino et al. (Science, 2021; N=25) demonstrated that 250 mg/day of NMN for 10 weeks improved skeletal muscle insulin sensitivity in postmenopausal women with prediabetes, providing the first human RCT evidence that NMN supplementation produces measurable metabolic effects [4]. That trial excluded immunocompromised individuals.

Organ Transplant Recipients

Solid-organ transplant recipients represent one of the most pharmacologically complex populations in medicine. No published clinical trial has tested NMN or NR in this group, and the theoretical risks are significant enough to warrant extreme caution.

Immunosuppressant Interactions

Transplant recipients rely on calcineurin inhibitors (tacrolimus, cyclosporine), mTOR inhibitors (sirolimus, everolimus), or antimetabolites (mycophenolate) to prevent graft rejection. NAD+ is a substrate for sirtuins, which regulate the same inflammatory and metabolic pathways these drugs target [5]. Sirtuin activation through NAD+ repletion could, in theory, modulate T-cell differentiation or macrophage polarization in ways that either augment or undermine immunosuppressive regimens.

Cyclosporine and tacrolimus are metabolized by CYP3A4 and transported by P-glycoprotein. While NR and NMN are not known CYP3A4 inhibitors or inducers, no formal drug-drug interaction study has been conducted [6]. The absence of data is not the same as the absence of risk.

Graft Ischemia-Reperfusion Injury

Preclinical data suggest NAD+ repletion could protect against ischemia-reperfusion injury (IRI). In a 2018 murine kidney transplant model, NMN administration (500 mg/kg IP) before reperfusion reduced tubular necrosis and improved early graft function [7]. These findings have not been replicated in humans, and the dose used in mice does not translate directly to oral supplementation.

A transplant nephrologist considering NAD+ precursors for a patient should verify stable trough levels of the immunosuppressant at baseline, start at the lowest available dose (NR 100 to 300 mg/day), and recheck trough levels at 2 and 4 weeks.

People Living With HIV

Chronic HIV infection, even when virally suppressed on antiretroviral therapy (ART), features persistent immune activation and accelerated biological aging. NAD+ metabolism is directly relevant to both.

NAD+ Depletion in Chronic HIV

A 2020 metabolomics study of 60 ART-suppressed individuals found that plasma NAD+ and NMN levels were 30 to 40% lower than in age-matched HIV-negative controls, correlating with CD38 overexpression on CD8+ T cells [8]. This depletion is thought to contribute to the excess cardiovascular, hepatic, and neurocognitive morbidity seen in long-term survivors.

Pilot Clinical Data

The most relevant human dataset comes from a phase I open-label study of NR (Niagen, 1,000 mg/day for 12 weeks) in 8 ART-suppressed adults. NR was well tolerated, raised whole-blood NAD+ by approximately 50%, and produced no clinically significant changes in CD4 count, HIV viral load, or hepatic transaminases [9]. The sample size makes it impossible to draw efficacy or safety conclusions, but the absence of viral rebound or immunologic flares is a necessary first signal.

Antiretroviral Interactions

Nucleoside reverse transcriptase inhibitors (NRTIs) such as tenofovir and emtricitabine are phosphorylated intracellularly by kinases that overlap with nucleotide salvage enzymes. A theoretical competition exists between NR phosphorylation by NRK1/2 and NRTI activation, but no pharmacokinetic interaction has been demonstrated in vivo [10]. The risk is low, though it remains unmeasured.

Patients on integrase strand transfer inhibitors (dolutegravir, bictegravir) or non-nucleoside reverse transcriptase inhibitors likely face even lower interaction risk, since those drug classes do not share the nucleotide salvage pathway.

Chronic Kidney Disease

NAD+ biosynthesis is impaired in CKD. This is not speculative.

The Tryptophan-Kynurenine Bottleneck

The de novo NAD+ synthesis pathway converts dietary tryptophan through the kynurenine pathway, with the final step catalyzed by quinolinate phosphoribosyltransferase (QPRT) in the kidney. A 2019 study by Tran et al. Published in the Journal of Clinical Investigation showed that QPRT expression drops markedly in injured kidneys, creating a biosynthetic bottleneck that depresses systemic NAD+ levels [11]. Supplementation with NMN bypasses this bottleneck by feeding the salvage pathway instead.

Animal Models of Renal Protection

In cisplatin-induced acute kidney injury (AKI) mouse models, NMN (500 mg/kg IP) administered before the insult preserved tubular ATP levels and reduced serum creatinine by 40% at 72 hours compared with vehicle [12]. Separate work in diabetic nephropathy models showed that NR supplementation (400 mg/kg/day) reduced albuminuria and glomerular hypertrophy over 8 weeks [13].

Human Dosing Gaps

No clinical trial has enrolled patients with eGFR <30 mL/min/1.73 m². The primary metabolite of both NMN and NR is nicotinamide (NAM), which is cleared renally. Accumulation of NAM could inhibit sirtuins (a paradoxical effect) and may cause hepatotoxicity at high concentrations [14]. For patients with CKD stages 4 to 5, starting doses should be conservative (NR 100 to 300 mg/day), with serum nicotinamide and liver function monitoring at 4-week intervals.

Autoimmune Disease and Chronic Inflammatory Conditions

NAD+ metabolism sits at the intersection of metabolism and immunity, making autoimmune populations both the most theoretically interesting and the most clinically uncertain group for supplementation.

Sirtuin-Mediated Immune Regulation

SIRT1 deacetylates NF-kB p65, reducing transcription of pro-inflammatory cytokines including TNF-alpha and IL-6 [15]. In rheumatoid arthritis synovial tissue, SIRT1 expression is paradoxically elevated yet functionally impaired due to NAD+ substrate limitation. Whether exogenous NAD+ repletion would restore anti-inflammatory SIRT1 activity or trigger compensatory upregulation of CD38 (further consuming NAD+) is unknown.

Multiple Sclerosis

A 2022 open-label pilot (N=15) of high-dose NR (3,000 mg/day for 12 weeks) in progressive multiple sclerosis found increases in cerebrospinal fluid NAD+ metabolites and a trend toward reduced neurofilament light chain, a marker of axonal damage [16]. The study was not powered for clinical endpoints. No adverse immunologic events occurred, though 3 participants reported mild flushing.

Practical Guidance

Patients on biologic immunosuppressants (adalimumab, rituximab, tocilizumab) should not begin NAD+ precursor supplementation without informing their prescribing rheumatologist or neurologist. Dose adjustments to biologics are unlikely to be needed based on current evidence, but surveillance for infection or disease flare is appropriate in the first 8 weeks.

Cancer Survivors and Active Malignancy

This is the population where caution is most warranted. NAD+ fuels PARP-mediated DNA repair, and some oncologists have raised the concern that replenishing NAD+ could protect tumor cells from DNA-damaging chemotherapy or radiation [17].

The Theoretical Risk

NAMPT, the rate-limiting enzyme in the NAD+ salvage pathway, is overexpressed in several solid tumors including colorectal, breast, and prostate cancers. Tumor cells upregulate NAMPT to sustain rapid proliferation [18]. Providing additional NAD+ substrate through NMN or NR supplementation could, in theory, support this metabolic demand.

Counterargument From Sirtuin Biology

SIRT1 activation has tumor-suppressive effects in some contexts, promoting p53 deacetylation and cell-cycle arrest. SIRT3 protects mitochondrial integrity and may limit the Warburg effect [19]. The net oncologic impact of NAD+ repletion likely depends on tumor type, stage, and concurrent therapy.

Clinical Bottom Line

No oncology society guidelines address NMN or NR use during or after cancer treatment. Patients with active malignancy should avoid NAD+ precursors until prospective data clarify the risk-benefit profile. Cancer survivors in remission (more than 2 years from last treatment) may consider supplementation under oncologist supervision with tumor marker surveillance.

Pregnancy, Lactation, and Pediatric Populations

No human trial of NMN or NR has enrolled pregnant or lactating women. Animal reproductive toxicology data are limited to a single rat study showing no teratogenicity at NMN doses up to 500 mg/kg/day, though pup weights were slightly lower at the highest dose [20]. NMN and NR should be discontinued at least 4 weeks before planned conception.

Pediatric use is unsupported by any clinical evidence. NAD+ metabolism in children differs from adults, with higher baseline NAMPT activity and less CD38-mediated degradation. There is no established indication for supplementation in patients under 18.

Geriatric Populations and Polypharmacy

Older adults (65+) are the group most likely to have depleted NAD+ and the most likely to benefit from repletion. They are also the most vulnerable to polypharmacy interactions.

Existing Trial Data in Older Adults

A randomized, double-blind trial of NR 1,000 mg/day in 40 healthy older adults (55 to 79 years) over 6 weeks raised NAD+ by 60% with no serious adverse events [21]. A separate 2023 trial of NMN 500 mg/day in 80 middle-aged adults showed improved 6-minute walk distance and reduced biological age markers after 60 days [22].

Polypharmacy Considerations

Older adults taking warfarin should have INR monitored after starting NMN or NR, as nicotinamide at high doses may potentiate anticoagulant effect through hepatic enzyme competition. Patients on metformin may see additive AMPK activation, which could theoretically increase lactic acidosis risk in those with borderline renal function [23].

Monitoring Recommendations Across All Special Populations

Baseline labs before starting NMN or NR in any high-risk group should include a comprehensive metabolic panel, CBC with differential, liver function tests (ALT, AST, GGT), fasting insulin, and uric acid. Nicotinamide can raise uric acid levels, and hyperuricemia is common in CKD and transplant populations [24].

Recheck labs at 4 weeks and 12 weeks. Any clinically significant rise in hepatic transaminases (more than 2x upper limit of normal) or uric acid (more than 9 mg/dL) should prompt discontinuation. For transplant recipients, add immunosuppressant trough levels at 2 and 4 weeks.